ANDA 203306, held by Natco. Lansoprazole.
As of Nov 21, 2026, ANDA 203306 (Lansoprazole), held by Natco, was first approved by FDA on Jan 13, 2016, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 13, 2016 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Lansoprazole15MG · capsule, delayed rel pellets;oral | Lansoprazole | OTC |
| Jul 21, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jul 21, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jul 21, 2020 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jan 13, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters